«

»

Lilly’s Barcitinib For Covid-19 – Too Little, Too Late?

Unless Lilly can show more impressive data for barcitinib combinations, such as in a study of barcitinib/remdesivir vs. dexamethasone/remdesivir, an EUA seems premature.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive